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Abstract 
 
The emergence of reproductive assistance like fertility treatments and assisted 
reproductive technologies (ART) in recent decades have provided new paths to pregnancy for 
many individuals. However, certain demographics in the US like low-income women and 
women of color are often excluded from utilizing these services on the basis of race, geography, 
and socioeconomic status. This in turn leads to significant disparities in access to and usage rates 
of such services. This research points out the perceived shortcomings in the current academic 
discussion surrounding fertility service disparities with the ultimate goal of expanding access to 
fertility assistance services for those who need it the most. Discussions about barriers to 
receiving fertility assistance services for marginalized demographics have been discussed at 
length in public health publications from governmental entities like the Centers for Disease 
Control and Prevention. Unfortunately, such discourse has become stagnant due to a lack of 
novel ideas and repetition of the same recommendations for eliminating access and usage 
disparities that have been proven ineffective by the fieldwork of social scientists. For example, 
many public health publications continually call for expansion of state insurance mandates to 
offer or cover fertility treatments and ART services in order to eliminate treatment disparities 
despite numerous publications revealing that these disparities persist even in states with 
comprehensive fertility assistance insurance mandates. To call attention to this pattern and to add 
nuance and depth to the current academic discussion, this research incorporates perspectives and 
findings from the fieldwork of social scientists studying fertility assistance services. The main 
conclusion made by this interdisciplinary research is that our nation's current fertility service 
disparities and biases effectively encourage the reproduction of those that fit ideological notions 
of motherhood and discourage the reproduction of those that do not. By addressing fertility 
treatment disparities from the integrated perspectives of both public health and social science, 
this research aims to both help lead to novel and effective solutions for eliminating such 
disparities and to encourage interdisciplinary endeavors across the fields of medicine, public 
health, and sociology in the future. Lastly, this paper calls for the inclusion of cancer-related 
infertility and the sub-discipline of oncofertility in future nationwide discussions about fertility 
treatment access and usage. 
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Most people have probably heard at least one story about a baby being a surprise, an 
accident, or a “honeymoon baby.” Hearing many iterations of these stories about abundant 
fertility may lead people to consider difficulties becoming pregnant a rare occurrence that afflicts 
only an unfortunate few. Contrary to stories of conception that result in the birth of a child, 
stories of infertility are a mostly hidden struggle. Yet this struggle is perhaps far more common 
than one might imagine. From 2011-2015 alone, 7.3 million women in the United States reported 
utilization of any type of fertility assistance service according to the comprehensive National 
Survey of Family Growth from the United States Center for Disease Control (CDC) (National 
Survey of Family Growth, “Infertility services”, 2016). Fertility assistance services and the 
disparities that exist in accessing and utilizing such services have been well-documented in the 
literature of recent decades, which will be at discussed at length throughout the course of this 
paper. 
With that being said, such discussions have become stagnant over the years, leading to 
regurgitation of the same statistics and vague pleas to eliminate fertility treatment disparities 
many times over. Moreover, some dialogue surrounding fertility treatment access and usage 
inequities fails to address a couple key aspects. First, cancer patients and the sub-discipline of 
oncofertility as a whole are often left out of the conversation. Second, many policy 
recommendations proposed in the literature focus solely on eliminating fertility-specific health 
disparities across racial, geographical, and socioeconomical lines, but fail to address the 
overarching disparities and discrimination in the field of healthcare that largely contribute to the 
existence of fertility-specific inequalities in the first place. 
 This paper will point out the perceived shortcomings in the current academic discussion 
surrounding fertility service disparities by analyzing demographical data through the lens of 
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social science literature. For example, the topic of state-mandated fertility service coverage and 
its effect on fertility treatment usage rates across racial and socioeconomic lines will be analyzed 
using this interdisciplinary approach. Doing so will hopefully add nuance and depth to the 
current discussion and encourage future interdisciplinary endeavors across the fields of medicine, 
public health, and sociology. To accomplish these goals, this paper will first address some 
common causes of infertility that necessitate the use of reproductive assistance services. Then, 
general information about different types of fertility treatments will be outlined, followed by 
barriers to accessing said services across racial, geographical, and socioeconomical lines for both 
the general population and the oncofertility population. Lastly, barriers to access will be 
explained and analyzed through social science perspectives in the hopes of encouraging dialogue 
that is geared toward making tangible strides to decrease both fertility-specific health inequities 
and societal-level inequities.  
 A more bottom-up, interdisciplinary approach to understanding and addressing the 
factors that limit access to and use of fertility services must be employed in the future to decrease 
the chances of individuals from marginalized minority groups slipping through the cracks and 
failing to receive the fertility services they seek. To do so, perspectives from the realm of social 
science that address the everyday realities of women experiencing limited access to fertility 
services must be incorporated into official nationwide discussions about infertility treatment 
disparities for both the general and cancer-afflicted populations. Whether intentional or not, our 
society’s current disparities and biases effectively encourage the reproduction of women that fit 
ideological notions of motherhood and discourage the reproduction of women that do not (Bell, 
2010). In order to more definitively tackle disparities in access to reproduction assistance, our 
country’s deeply rooted biases and overarching health inequities must also be addressed. 
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PART I: INTRODUCTION & BACKGROUND 
Infertility and Impaired Fecundity 
Before delving into the specifics of fertility, infertility, and everything in between, it is 
useful to define some key terms. While there is no standard definition for infertility that is 
consistent across all relevant organizations and academic disciplines, infertility is often described 
as the inability of married couples to conceive a clinical pregnancy after one year or more of 
trying, as described in the CDC’s National Public Health Action Plan for the Detection, 
Prevention, and Management of Infertility. A term adjacent to infertility is impaired fecundity, 
which refers to individuals of any marital status who are unable to achieve a viable pregnancy 
after three years of unprotected intercourse (“National Public Health Action Plan”, 2014). If 
infertility and impaired fecundity is the failure to achieve a pregnancy in a timely manner, 
fertility can be considered the ability to achieve a pregnancy within a 12-month period of 
attempts to conceive.1 Although men in addition to women experience fertility struggles, the 
scope of this paper will focus on women. 
Discussions of fertility and infertility have been on the rise in the United States in recent 
decades, likely due in part to women having their first children later in life than in previous 
decades. One report summarizing vital birth statistics in the US found that the percentage of 
women giving birth to their first child who were aged 30 or more years increased 21% in 35 
years with percentages rising from only 5% of women in 1975 to 26% of women in 2010 
(Hamilton, Martin, & Ventura, 2011). Furthermore, infertility rates increase in both men and 
women as paternal and maternal age increase due to a reduction in sperm abundance and quality 
 
1 While the aim of the paper is to discuss fertility issues between couples consisting of cis female and a cis male, it is 
worth noting that the general nature of these definitions does not account for the wide array of fertility struggles 
faced by people in communities like the LGBTQ+ community and beyond. 
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in men and a decrease in oocyte quality and ovulatory function in women. In addition to the 
aforementioned causes for increased infertility in women as maternal age increases, women’s 
risk of experiencing other fertility complications like endometriosis and tubal factor infertility 
due to fallopian tube scarring or obstruction also increase (CDC, 2014). Other common causes of 
fertility issues in women are complications due to autoimmune disorders, abnormal reproductive 
tract growths such as uterine fibroids, sexually transmitted infections (STIs) like Chlamydia 
trachomatis and human papillomaviruses, and hormonal conditions like polycystic ovary 
syndrome (“What are some common causes of female infertility?”, 2017). While it is true that 
some of these common causes of infertility like STIs are preventable in most cases, women from 
certain demographics in the US like black women are disproportionately affected by particular 
risk factors like uterine fibroids and chlamydia (“National Public Health Action Plan”, 2014). 
Simply preventing common causes of infertility is not always a feasible solution to eliminating 
fertility struggles for all populations of women, therefore it remains productive to discuss 
infertility interventions for those who have already been afflicted with impaired fecundity or 
infertility or those who will become affected in the future.  
Another cause of infertility for child-bearing individuals is cancer. When a child is 10 
years old, he or she possesses a 1.67% chance of receiving a cancer diagnosis in the next 30 
years, or by the time they have aged 40 years (White et al, 2015). While this may not seem like a 
large percentage, this means that just under 5.5 million 10-year-olds in the US will receive a 
cancer diagnosis before their years of childbearing are over. Similarly, over 135,000 people 
under the age of 45 will be diagnosed with cancer each year, with approximately one-half of 
these individuals being females (National Cancer Institute, 2018). Fortunately, not all cancers 
and their treatments result in fertility issues. If a cancer can be treated surgically or with minimal 
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intervention, a person’s fertility should not be affected. Cancers that do involve high-intensity 
intervention, however, create the possibility of cancer-related infertility. 
Generally speaking, the most common causes of cancer-related infertility in women are 
often caused by cytotoxic chemotherapy and radiotherapy. Depending on the specific type of 
chemotherapy, cytotoxic chemotherapy can result in gonadal damage (Salama, Isachenko, 
Rahimi, & Mallmann, 2017). Alkylating agents, a class of chemotherapy drugs that damage the 
DNA of cancer cells and in turn prevent any further growth, are used as a standard line of 
therapy against a variety of cancer types. Alkylating agents exhibit dose-dependent germline 
toxicity or “gonadotoxicity” by also damaging ovarian and fallopian tissues. Even more 
damaging to the female reproductive tract is radiation therapy or “radiotherapy”, which is used in 
a targeted fashion for the treatment of solid tumor cancers or is delivered to the whole body in 
the case of total body irradiation used for non-solid tumor hematologic malignancies. Because of 
its ability to kill over 50% of a female’s ovarian follicles with just 2 Gy of radiation, 
radiotherapy can cause gonadotoxicity, early menopause, and complete ovarian failure. While 
only 2 Gy of radiation is sufficient to largely decrease a woman’s fertility options, some 
treatment courses require closer to 10 Gy of radiation or more (Lee, 2017). Despite the ability of 
cancer treatments to destroy female reproductive tracts, cancer-related infertility is often 
excluded from lists of the most common and damaging medical conditions that can decrease 
infertility and impaired fecundity for women who later try to conceive. 
The aforementioned forms of cancer treatment can greatly decrease a woman’s chance of 
conceiving and giving birth to a healthy infant should she later attempt to become pregnant. One 
study assessing the long-term effects of these treatments on pregnancy outcomes for cancer 
survivors found that the pregnancy rate among people who have received treatment for cancer is 
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around 20% lower than the general population. Both alkylating chemotherapy and radiation can 
cause generalized gonadotoxicity, but radiotherapy has been shown to also damage the uterus 
and consequently increase the risk of later experiencing spontaneous abortion, premature birth, 
and giving birth to infants with a low birth weight (Lee, 2017). As briefly mentioned above, 
greater than or equal to 10 Gy of radiotherapy is the amount of radiation standardly used in 
treatment plans for individuals with cancer of the blood or immune system. Unfortunately, 
pregnancy rates decrease 82% when exposed to this amount of radiation (Green, Kawashima, & 
Leisenring, 2009). Anti-cancer treatment is most damaging to those that receive treatment at a 
younger age, with cancer survivors that undergo therapy before the age of 20 experiencing 
infertility at three times the rate of those who have not undergone cancer treatment (Barton, 
2013). For this reason, cancers that disproportionately affect younger individuals who are still of 
child-bearing potential deserve special attention in nationwide discussions about fertility. 
 One of the types of cancer that largely affects children and adolescents is blood cancer. 
Blood cancers, also known as hematological malignancies, are a broad category of cancer that 
consists of leukemia, lymphoma, and myeloma. While hematological malignancies account for 
only 7-9% of new cancer cases for women of all ages, specific types of blood cancers like 
leukemia pose a large threat to females before and during their reproductive years. Leukemia 
accounts for 31% of all cancer in pre-pubertal girls aged 0-14 and 12% of cancer cases in 
adolescents aged 15-19 years (Siegel, 2018; Leukemia & Lymphoma Society, 2016). Advances 
in medical technology, early detection and diagnosis, and high-intensity treatment in the last half 
a century of hematological cancer treatment has increased 5-year survival rate from 34.1% in the 
1970s to 62% for all leukemia patients, with patients younger than 45 years reaching a 75.4% 5-
year survival rate (National Cancer Institute, 2016). While this increase in survival is an 
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outstanding feat, the very high-intensity treatment that makes this increased survival possible 
also simultaneously decimates the reproductive tracts of those that undergo the therapy. 
Because blood cancers recur at a high rate compared to solid mass cancers, blood cancer 
survivors often experience disease that relapses or proves resistant to multiple lines of therapy 
that often necessitates the use of hematopoietic stem cell transplantation (HSCT) as the most 
promising line of treatment (Lee, 2017). Unfortunately, those that undergo HSCT experience 
infertility at 36 times the rate of those that do not undergo an HSCT (Carter et al, 2006). Though 
sometimes overlooked in discussions of fertility preservation and treatments, cancer survivors 
whose chances of reproduction have been lessened by treatments like cytotoxic chemotherapy 
and radiotherapy should be included in future discussions. 
 
Fertility Treatments & ART Services for the General Population 
Fertility issues that affect both the regular population and the cancer-afflicted population 
often cause people to turn to their biomedical providers for assistance in ameliorating their 
struggles to conceive, carry a pregnancy to term, or both. This reproductive assistance falls into 
the following two main categories: general fertility treatment and assisted reproductive 
technologies (ART). General fertility treatments options are the less involved of the two options, 
consisting mostly of non-invasive and low-tech interventions, which is likely why this category 
of fertility assistance is most prevalent. Of the women aged 15-44 who participated in the 2015-
2017 CDC National Survey of Family Growth, 12.7% reported having ever utilized any type of 
reproductive assistance including both general fertility treatment and ART. Notably, only 0.6% 
of women reported utilization of ART services. In the realm of general fertility treatment 
options, 6.7% of women received general medical fertility advice, 5.8% had themselves or their 
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partners tested for infertility factors, 5.1% received help preventing miscarriage, 4.3% received 
ovulation medication, 1.4% underwent artificial insemination, and 0.8% underwent surgery to 
reverse tubal blockage (National Survey of Family Growth, “Infertility services”, 2019) (Fig. 1). 
Understandably, the least invasive and likely least expensive fertility services like general 
medical advice and help preventing a miscarriage were most prevalent, whereas high-
intervention ART services were least prevalent. 
 
 
Figure 1. Percentage of women aged 15-44 surveyed in the 2015-2017 CDC National 
Survey of Family Growth who received each type of reproductive assistance. 
 
 
Compared to general fertility treatment services, ART services are more involved and 
more costly. ART for females can be defined as a type of fertility service in which oocytes are 
surgically extracted from the female and fertilized ex vivo in a laboratory setting with the 
purpose of providing the user with expanded fertility options (Art Success Rates, 2019). Using 
this definition of ART, intrauterine insemination or “artificial insemination” does not technically 
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constitute as an ART service because the female’s eggs are never extracted and handled ex vivo. 
The vast majority of ART services involve in vitro fertilization (IVF) procedures, which consists 
most routinely of stimulating oocyte production with gonadotropin-based ovulation medication, 
surgically removing and fertilizing oocytes, and re-implanting the fertilized embryo into a 
woman’s uterus via the cervix (Art Success Rates, 2019). In the most recent national ART 
summary report released by the CDC in 2016, over 99% of performed ART procedures that year 
involved the use of IVF. The two other types of ART services for females which place an egg or 
a zygote directly into a woman’s fallopian tube, gamete intrafallopian transfer and zygote 
intrafallopian transfer, require surgical incisions and general anesthesia and are therefore rarely 
implemented (2016 ART National Summary Report, 2018). 
As previously alluded to, ART procedures like IVF are more costly than general non-
ART fertility services because the former often require the labor of and collaboration among 
multiple physicians and laboratory staff members. Including the ovulation medications, the 
median out-of-pocket cost of a cycle of IVF in the US is $19,200. Taking into account that the 
average number of IVF cycles required to conceive is 2.7, the average total IVF cost is $51,840 
(Ethics Committee of the ASMR). Although it carries a hefty price tag, the development of ART 
in recent decades has created new pathways to conception that were previously unavailable for 
those who were unable to conceive or achieve a clinical pregnancy even after exhausting all non-
ART modes of fertility treatment.  
It is worth noting that the IVF process can be personalized based on each individual’s 
reason for using ART and on her life stage, so a complete IVF cycle does not always take place 
within a short window of time. For example, a single woman may elect to extract and freeze 
(“cryopreserve”) some of her oocytes in the hopes of maintaining many reproductive options for 
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the future, such as completion of the IVF process using the sperm of a future partner or sperm 
donor. This is in fact so common that the ontological category of “anticipated infertility” has 
emerged in sociological publications to describe “the condition in which one believes one may 
be infertile in the future” (Martin, 2010). This idea of anticipated infertility is relevant to the 
general population and is the driving principle behind the use of fertility preservation techniques 
for female cancer patients. Furthermore, if a person’s choice of sperm is known at the start of the 
IVF process as is often the case with couples undergoing ART services, fertilized embryos that 
were generated but not implanted during a previous IVF cycle can also be cryopreserved for 
possible future usage. Lastly, 3% of ART cycles involve the use of a surrogate either by choice 
or by necessity if the woman is incapable of carrying and delivering a healthy infant (2016 ART 
National Summary Report, 2018). A flowchart of fertility treatment options spanning both the 
realms of general infertility treatment and ART can be summarized in Figure 2. 2 
 
 
 
 
2 Please note that this diagram does not cover all fertility treatment options for males because this paper is focused 
on female fertility. This is not intended to be an exhaustive list of every single fertility treatment service on the 
market, but rather to serve as general guideline for a logical order in which to proceed with the most common forms 
of treatment in the realm of biomedicine. Every individual is unique and should create an appropriate plan of action 
with their providers. 
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 Figure 2. Summary of fertility treatment options including both general fertility treatments and 
ART services for the female general population.   
 
Before any discrepancies in access to or utilization of ART services can be addressed, 
accurate ART usage rates must be collected and organized. The National ART Surveillance 
System (NASS), a standardized data-reporting system led by the CDC, does just this. Using data 
obtained from US fertility clinics, medical providers can present those pursuing ART services 
with reasonable estimates of success based on data from previous people who have similar 
demographics, medical history, and infertility diagnoses (National Art Surveillance, 2019). In 
2016 alone, 263,577 ART cycles were performed at the 463 verified ART clinics in the US. 
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Excluding the 25% of cycles that were initiated with the intention to cryopreserve any resulting 
oocytes or embryos, the 75% of cycles that were initiated with the intention to proceed to 
embryo transfer and live birth resulted in the birth of 76, 897 live infants. In terms of general 
outcomes, women under the age of 40 achieved a pregnancy per ART cycle success rate of 
29.0% and a live birth per cycle success rate of 23.5% (2016 ART National Summary Report, 
2018).  Continued availability of comprehensive ART data plays a key role in future discussions 
about fertility treatment access. 
 
Fertility Treatments & ART Services for the Oncofertility Population 
 Though Figure 2 serves as a general guideline that can apply to most individuals, certain 
groups of people experience unique medical circumstances that necessitate especially 
individualized general fertility and ART treatment plans. Individuals who are about to receive or 
have already received fertility-compromising cancer treatment are an example of such a group. If 
a female patient who is about to undergo anti-cancer therapy is post-pubertal, in most cases the 
individual can undergo ovarian stimulation and oocyte retrieval followed by cryopreservation 
like any person unafflicted by cancer can do (Salama et al, 2017).3 Because of recent novel 
innovations like emergency IVF or “random start” protocols that allow for oocyte stimulation 
and retrieval at any point in a female’s menstrual cycle, oocytes can be stimulated and retrieved 
in an average of only two weeks opposed to the 2-6 week time frame for conventional oocyte 
retrieval (Cakmak & Rosen, 2015). This shortening of the egg-retrieval process timeline 
 
3 The process of gonadal stimulation and subsequent oocyte retrieval is usually the same process for individuals 
from both the general and oncofertility populations. That being said, data from CDC’s NASS suggests that success 
rates for pregnancy and live birth are higher when fresh eggs opposed to frozen eggs are used. Because oncofertility 
patients’ only option is cryopreservation of samples, their chances of reproduction using IVF is slightly less than 
that of the general population (National Art Surveillance, 2019). 
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decreases the likelihood that a woman will opt out of fertility preserving options to avoid a 
significant delay in receiving chemotherapy or radiation, as is often the case when dealing with 
blood cancers that require immediate anti-cancer therapy intervention (Salama et al, 2017). 
While the random start method has expanded fertility preservation options for many post-
pubertal females with cancer, certain high-risk cases require immediate therapeutic interventions 
and thus cannot wait even two weeks for an oocyte harvest. Furthermore, traditional IVF 
processes involving ovarian stimulation are not applicable to all individuals.  
 Prepubescent girls cannot undergo ovarian stimulation and subsequent oocyte retrieval 
due to their inactive hypothalamic-pituitary-ovarian axes (Salama et al, 2017). Consequently, the 
only current fertility option that exists for prepubescent girls is a type of assisted reproductive 
technology called ovarian tissue cryopreservation. This process consists of collecting immature 
oocytes from the ovaries to later mature outside the body in preparation for fertilization and 
eventual transfer into the uterus (Dillon & Gracia, 2012). Finally, women diagnosed with 
hematological malignancies like lymphoma and leukemia are faced with uniquely difficult 
fertility preservation prospects. In some cases, oocytes or ovarian tissue extracted from 
prepubescent or postpubescent females with blood cancer can be contaminated with malignant 
cells and therefore cannot be transplanted back into the woman’s bodies after remission has been 
achieved. In attempts to restore fertility for this population, scientists are in the process of 
developing an artificial human ovary method in which ovarian tissue is extracted, stripped of any 
cells to eliminate any possibility of malignant cell contamination, new ovarian follicles are 
matured ex vivo in the artificial ovary, and the ovary is transplanted back into the woman after 
their disease is in remission (Amorim & Shikanov, 2016). Benefits of this method include its 
applicability to both prepubescent and postpubescent women and its possibility of fertility 
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restoration capabilities without the use of ovarian stimulation and IVF to become pregnant. This 
is especially useful in cases where people are unwilling or unable to undergo the IVF process. A 
summary of all the aforementioned information, can be found below (Fig. 3).  
 
Figure 3. Summary of fertility treatment options for general fertility treatments and ART 
services for the female oncofertility population. Adapted from Dillon & Gracia, 2012. 
 
 
In attempts to distribute a consolidated and updated message to oncologists all over the 
US, the American Society of Clinical Oncology (ASCO) has published clinical practice 
guidelines on fertility preservation in patients with cancer. In addition to upholding the 
information found in Figure 3, oncofertility experts emphasize some other important 
recommendations. First, oncology providers should discuss any possibility of impaired fecundity 
or infertility with patients and their guardians if applicable as soon as possible. Second, providers 
should be prepared to refer all at-risk patients to reproductive endocrinologists in a timely 
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manner even if they are only focused on what they can do as an oncologist, which is to create an 
anti-cancer treatment plan (Oktay et al, 2018). Because impaired fecundity and infertility 
continue to persist in the US due to both health disparities and illnesses like cancer, 
understanding the common causes of these fertility issues and the ways both general fertility 
services and ART services can help ameliorate the problem remain a key part of the discussion 
surrounding fertility services.   
The ASCO guidelines on fertility preservation for cancer patients gain additional 
legitimacy when considered alongside the fact that unsatisfactory percentages of oncologists 
were providing childbearing-aged patients with fertility referrals, despite the literature outlining a 
need for such services. One review of the psychosocial issues faced by adolescents and young 
adult cancer-survivors found that matters of fertility deeply affected a person’s identity, well-
being, and future life plans regardless of gender (Crawshaw, 2010). Another study, which 
assessed the experiences of young women with breast cancer, even more strongly substantiates 
the need for fertility referrals for cancer patients. Of the surveyed individuals, 29% of the women 
stated that they would sacrifice some of the efficacy of their anti-cancer therapy by choosing a 
less effective lower intensity treatment if it decreased their chance of sterility (Partridge et al, 
2004). While these sources demonstrate the importance of fertility preservation to young cancer 
patients, other sources show that some oncologists do not consider fertility a priority relative to 
the cancer, among other reasons for not providing patients with referrals.  
As of 2008, only 47% of surveyed oncologists stated routine referral of childbearing-
aged cancer patients to reproductive endocrinologists. Things like hesitance to initiate intimate 
conversations about fertility, a lack of allocated appointment time to discuss non-cancer related 
matters, and perceptions that the patient does not have time to address fertility concerns before 
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receiving cancer treatment were cited as reasons for not providing referrals (Quinn et al, 2008). 
Some oncologists were also not sufficiently educated in matters of oncofertility, so they did not 
know to always refer patients out for fertility consults. Lack of oncofertility knowledge was the 
main reason stated by oncologists in a 2010 study which found that only 82% of surveyed 
oncologists had ever referred their patients to a reproductive endocrinologist, over 50% admitted 
to “rarely referring,” and 30% of non-gynecological oncologists claimed to “rarely consider” a 
female patient’s desire for fertility (Forman et al, 2010). These discoveries illustrate why there 
needs to be more emphasis placed on making oncology medical providers proficient in the basics 
of oncofertility. 
 
PART II: DEMOGRAPHICS 
 
Race/Ethnicity 
 
 One factor across which disparities in access to and utilization of fertility assistance 
services can be found is race/ethnicity. It has been well-documented in the demographical 
literature of recent decades that non-white women generally have lower rates of fertility 
assistance usage compared white women, especially for black women and non-white Hispanic 
women (Chandra et al, 2014). Although a logical explanation for this disparity would be that 
perhaps infertility and impaired fecundity are less prevalent in black and Hispanic populations. 
In reality, the opposite pattern has been found. According to various studies, black and Hispanic 
women report higher rates of impaired fecundity and infertility (Wellons et al, 2009 & 
Huddleston et al, 2010). This gap in infertility rates was highest between black women and white 
women, with one study reporting infertility in 10.5% of surveyed black women but in only 6.4% 
of white women (Huddleston et al, 2010). Some demographic articles are quick to indirectly 
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blame black women for their fertility struggles, citing higher rates of chlamydia and 
subsequently higher tubal factor infertility rates in this population (Huddleston et al, 2010). 
Other articles, however, show that black women are two times more likely to have experienced 
infertility than white women even after adjusting for SES and infertility risk factors like STIs and 
uterine fibroids (Wellons et al, 2009). Certain populations like black women are undergoing less 
fertility assistance despite greater affliction with infertility, signifying that something deeper is 
going on here that is preventing certain minority groups from receiving the care they seek. This 
paper argues that the something deeper are the broad, societal-level inequalities that specific 
disparities like fertility access and usage are mere symptoms of (Douthit et al, 2015). Both the 
small-scale and large-scale issues must be addressed together in order to achieve the best 
possible chance of creating lasting solutions to pervasive healthcare disparities.    
 Another specific example of how fertility treatment access and usage differ across racial 
lines is marital status. One study found that the percentages of women aged 40-44 years who had 
ever been married differed across racial lines. While 88% of non-Hispanic white women reported 
at least one marriage, only 63% of surveyed black women had ever been married (Raley, 
Sweeney, & Wondra, 2016). Interestingly, another study found that one in five medical providers 
refused to allow unmarried women to participate in ART programs (Gurmankin, Caplan & 
Braverman, 2005). Considering these two sources together adds another layer in the complicated 
story that is fertility access barriers for black women. 
 Lastly, race also has a significant effect on cancer survival rates. According to some 
sources, cancer can have a disproportionately severe impact on select minority groups 
(Mohapatra, 2015; Cancer Facts & Figures for African Americans, 2019). From 2016-2018, the 
cancer death rate for all forms of cancer was 14% higher in black women than in white women 
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(Cancer Facts & Figures for African Americans, 2019). While these disproportionate cancer rates 
in black women are largely explained by disproportionate levels of poverty, it is nonetheless 
troubling. It is especially troubling when considered alongside the fact that discrimination can 
contribute to cancer disparities by racial and ethnic minorities tending to receive a lower-quality 
of healthcare than majority populations even when factors like age, state of cancer, and insurance 
status are adjusted for (“Cancer Facts & Figures, 2019). This further proves that overarching 
racially motivated healthcare inequalities and biases must be addressed for people in both the 
general and oncofertility populations because they can ultimately contribute to a person’s 
fertility. 
 
Geography 
Several studies and official government reports have outlined the disparities in access to 
fertility services across geographical lines (Harris et al, 2017; 2016 ART National Summary 
Report, 2018). The results of Harris et. al’s population-based cross-sectional study on 
geographical access to ART in the US revealed that ART centers and specialists are unequally 
distributed throughout the country, with greater clinic densities in states with mandated insurance 
coverage and higher per capita incomes. The study also indicated that 39.6% of reproductive-
aged US women have limited or nonexistent access to nearby ART services due to 
maldistribution of clinics that render many rural individuals without a feasible option for 
reproductive assistance (Harris et al, 2017). Similarly, the CDC’s 2016 National Summary 
Report on Assisted Reproductive Technologies included a map showing ART-providing clinic 
densities across the country, which showed a large number of clinics in major metropolitan areas 
like Seattle, Los Angeles, San Francisco, Dallas/Fort Worth, Boston, and New York (2016 ART 
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National Summary Report, 2018). While it is both unfortunate and troubling that ART clinics are 
maldistributed to favor urban locales over rural locales and states with mandated fertility service 
coverage over states without, it is important to note that these effects are partly unavoidable. 
Because the number of highly specialized reproductive endocrinologists in the US are limited, 
not every community in the US has the luxury of being in close proximity to an ART-providing 
physician and a laboratory capable of the benchwork required for procedures like IVF. What can 
be changed and needs to be addressed, however, is the fact that the fertility treatment service 
inequalities are a symptom of the broader issue of certain regions and populations in the US 
being medically disenfranchised from most or all types of healthcare, not just specialties like 
fertility (Douthit et al, 2015). If specific fertility-related geographic concerns are not addressed 
in conjunction with the overarching trend of general medical disenfranchisement, it is likely that 
individuals in these regions and populations will continue to slip through the cracks and fail to 
receive the fertility services that they seek. 
 Another deciding factor that can contribute to fertility treatment access across 
geographical lines is the state in which an individual resides. Starting in the late 1980s, states in 
the US began enacting laws about insurance mandates for infertility coverage with the intention 
of reducing healthcare disparities in the realm of fertility and pregnancy. These infertility 
coverage laws are on a state-by-state basis and can vary in type of service covered and the extent 
to which insurance companies have to cover such services. For example, laws in some states like 
California and Texas only require that insurance companies offer certain fertility testing and 
treatment services, but each employer has the ability to decide if they will offer any or all of the 
services to their employees. The other 15 of the 17 total states that have enacted fertility service 
insurance laws, however, have more involved mandates to cover particular fertility treatments 
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like. Interestingly, several of these laws include stipulations that allow religious organizations to 
be exempt from offering infertility service coverage (“Infertility Coverage by State”). Similarly, 
traditionally conservative states like Arkansas require that any IVF covered under the state 
insurance mandate must occur by the woman’s egg becoming fertilized only by her spouse’s 
sperm, which is inherently discriminatory against non-married individuals and queer couples 
(“State Infertility Insurance Laws). Lastly, only 7 out of the 17 states with fertility insurance 
mandates include sections of the law that provide paths to insurance-covered treatment for cases 
of medical treatment-induced or “iatrogenic” infertility (“Infertility Coverage by State). Because 
cancer survivors whose fertility has been compromised by anti-cancer therapy would be 
considered to have the diagnosis of iatrogenic infertility, those who suffer from cancer-related 
infertility are left without reasonable paths to insurance-covered treatment in over half of the 
states with mandates. This unfortunate situation is a good example of why those afflicted with 
cancer will continue to slip through the healthcare cracks if oncofertility remains excluded from 
important fertility access reports and academic discussions in the future. 
 
Socioeconomic Status 
 Some of the state-mandated infertility insurance coverage laws include stipulations that 
exclude certain groups and allow for employer discretion regarding whether or not they wish to 
extend coverage options to their employees. While these laws are somewhat exclusionary, it 
should be recalled that this is all taking place within the context of people who actually have 
insurance and live in states with fertility coverage insurance mandates. This leaves particular 
groups like the unemployed, the uninsured, and those who do not reside in states with mandated 
fertility insurance coverage at risk of slipping through the cracks. Those who are wealthy enough 
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can either purchase their own insurance in times of unemployment or simply pay out of pocket 
for fertility services. For these reasons, much of the matter ultimately comes down to an 
individual’s socioeconomic status.  
It is well understood that people of higher SES have greater utilization rates of infertility 
services. According to cycles of the NSFG from 1982-2010, the ever-use of infertility services 
was highest among women with greater annual incomes, which is one of the measures of SES. 
Twenty-one percent of women with household incomes at least four times the national poverty 
level had ever used a form of fertility assistance, whereas this number was 13% for women with 
below-poverty income levels. Other measures of SES like education attainment reveal a similar 
pattern. For instance, 19% women aged 25 years or older who possessed at least a master’s level 
degree reported using medical advice to become pregnant, compared to the 6.4% rate reported by 
women who did not graduate from high school (Chandra et al, 2014). These data suggest that 
only individuals who can afford to purchase fertility assistance services and who achieved a level 
of higher education are effectively aided and encouraged to reproduce by society. 
 Socioeconomic status is also related to cancer in that those who are of lower SES have 
poorer cancer-related health outcomes than their higher SES counterparts. First, disparities in 
incidences of certain cancers across socioeconomic lines do exist. However, this finding is 
generally explained by environmental and lifestyle factors like greater levels of exposure to 
mutagens and carcinogens and less healthful behaviors such as cigarette smoking and poor diet 
(Haynes & Smedley, 1999). Nevertheless, a person’s social class can increase one’s chances of 
developing cancer and consequently requiring fertility services for iatrogenic infertility. More 
significantly, cancer survival rates of low-SES people are 10-15% lower than in Americans who 
are of middle or higher SES populations regardless of a person’s race or ethnicity (“Cancer Facts 
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& Figures 2019”). This statistic shows that although a person’s race and socioeconomic status 
can often be related, this link between SES and cancer is caused only by socioeconomic status. 
Although the statistical and demographic information provided in the preceding paragraphs is 
helpful in understanding and pinpointing gaps in access to fertility services for certain 
populations in the US, situating these statistics and discussing them in a social science context 
allows for a more nuanced and complete understanding of why these disparities exist. This 
deeper understanding of fertility service access and usage disparities increases the chances of 
these issues being solved once and for all. 
 
PART III: ANALYSIS 
While outlining demographical information and statistics is a necessary step in the overall 
goal of expanding access and utilization of various infertility treatment options, only through 
contextualizing these findings through more social science-oriented sources and perspectives do 
we arrive at a more complex and thorough understanding of the problem. Part II of this paper 
was divided into sections according to race/ethnicity, geography, and socioeconomic status, but 
the analysis portion will be divided into sections by topic. This is being done because in reality, a 
person’s race and socioeconomic status are not stand-alone categories into which an individual 
cleanly fits. Rather, they are interrelated entities that interact with and shape each other to 
uniquely affect the experiences of any given person (Crenshaw, 1989). For this reason, this 
portion of the paper will first attempt to dismantle the myth of expanding insurance mandates as 
the “cure-all” for fertility treatment access issues, followed by a discussion of the explicit and 
implicit ways in which the reproduction of some is encouraged, while the reproduction of others 
is not. 
  Gilbert 23 
 
Insurance Mandates as the “Cure-all”: Busting the Myth 
Demographic-based articles often include vague calls to action or provide possible 
solutions that have already been proven ineffective by the literature. The disconnect between 
demographical public health research and social science research contributes to the unfortunate 
occurrence of some individuals being left without access to fertility treatment options. It is worth 
noting that the authors of such texts are generally in the business of proposing policy 
recommendations and not implementing them, making the broad nature of the recommendations 
justifiable and valid. What is more difficult to overlook, however, is the repeated 
recommendation of policy changes that have been proven unsuccessful in yielding the intended 
result of expanding fertility assistance services to marginalized and previously excluded 
demographics. 
Review articles summarizing the main challenges faced by individuals seeking access to 
infertility services in the US provide useful statistics and draw attention to important patterns in 
certain demographics like disparities in access to treatment across racial, socioeconomic, and 
geographical lines. The authors of these papers also often do so with a spirit of inclusion and 
social justice, yet the complexities inherent to this topic are not always engaged with. Instead of 
reiterating the same suboptimal pleas to decrease infertility disparities, this paper aims to urge 
future policy recommenders to utilize a more interdisciplinary and intersectional approach to 
tackling these issues. While no specific policy recommendations or measures for reducing health 
inequities will be offered, this paper instead hopes to emphasize the advantage inherent to this 
interdisciplinary approach. This will be accomplished through the providing of concrete 
examples that illustrate the enhanced level of clarity that can be achieved when a fertility 
treatment access inequity is approached from more than one perspective. 
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To their credit, the authors of demographic-focused analyses of fertility treatment 
disparities speak very compassionately about inequalities in fertility treatment access that affect 
different groups. One paper emphasizes that “it is socially unjust in that the right to build a 
family in the face of infertility appears to have become a function of economic prowess” (Adashi 
& Dean, 2017).  It is admirable that the authors consider it a “central moral imperative” to 
improve public underwriting and insurance mandates for infertility and ART service coverage in 
attempts to expand access to those that otherwise would not be able to afford such services. 
However, literature that is more social science oriented has proven that inequalities persist even 
in states with mandated insurance coverage for fertility treatments (Jain & Hornstein, 2005; 
Bitler & Schmidt, 2006). Likewise, the Ethics Committee of the ASRM stresses that “starting a 
family is a basic human right” and cite the statistic that state-mandated fertility insurance 
coverage has resulted in a three-fold increase in utilization of fertility services in states with 
mandates as a reason why it is also an ethical imperative to increase such mandates (Ethics 
Committee of the ASRM, 2015). The authors of these review articles mean well when outlining 
the challenges to this topic and offering possible solutions, but they tend to neglect the realities 
of everyday life for many of the low-income and marginalized women to which these very 
papers aim to expand fertility treatment access. For example, the first author of the Adashi et al 
paper’s status as a physician at Brown University makes her qualified to discuss public health 
concerns like maldistribution of ART clinics across the US. But perhaps this leaves her out of 
touch with the realities of the people she intends to help—a mistake less frequently made by 
those trained in the social sciences. 
For example, there are several sources pre-dating Adashi & Dean (2017) and other 
demographic-based publications that emphasize the persistence of infertility treatment access 
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disparities across socioeconomic and geographical divides even in states with mandated 
infertility coverage. The state of Massachusetts has had mandated and comprehensive insurance 
coverage for infertility services including IVF since 1987 (“State Infertility Insurance Laws”). 
Accordingly, Massachusetts will be used as a case study in the following paragraphs to provide 
some concrete examples from studies that have suggested the existence of persistent disparities 
in access to and use of fertility treatment services despite the implementation of insurance 
mandates. 
Because overall fertility service usage was found to be greater in states with mandated 
infertility coverage compared to states without mandated insurance, researchers hoped that those 
who received fertility treatment in Massachusetts but not in states without mandates were from 
traditionally under-privileged and medically under-resourced communities (Jain, Harlow & 
Horsntein, 2002). Instead of extending services to groups like women of color or women of low 
SES who were previously financially excluded from such services, one Massachusetts study 
reported that the majority of those accessing fertility services post-mandate were actually white, 
well-educated women (Jain & Hornstein, 2005). While it is true that the majority of those 
accessing services were white women, this does not statistically differ from the general 
population of Massachusetts where 84.5% of women in the state at the time of the study 
identified as white (χ2 p-value: 0.057). Hispanic/Latinx women, however, were underrepresented 
in the number of those who sought infertility services compared to the general Massachusetts 
population per the 2000 census. Although Hispanic/Latinx women comprised of 6.8% of the 
general population, they made up only 3.9% of the women accessing fertility services (χ2 p-
value: 0.011). This study serves as an example for how disparities in fertility treatment access 
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across racial lines are often not eliminated by the implementation of mandated insurance 
platforms. 
In the same study, the disparities across socioeconomic lines were even more remarkable. 
Despite 15.1% of the adult Massachusetts population lacking completion of a high-school level 
education and 45.3% obtaining a high school diploma as their highest education level, not a 
single person without a high school diploma and only 6.4% of those with only a high school 
diploma sought infertility treatment (χ2 p-value: <0.001). Alternatively, nearly half of those that 
pursued infertility treatment possessed master’s or other advanced degrees even though these 
individuals comprised only 12.4% of the general population of Massachusetts women (χ2 p-
value: <0.001). Furthermore, 60.4% of women treated earned greater than or equal to $100,000 
per year even though this was the annual income of only 17.7% of the general population (χ2 p-
value: <0.001) (Jain & Hornstein, 2005). A critical takeaway from this study is that future 
discussions about eliminating fertility treatment disparities should especially emphasize 
socioeconomical factors, as they appear to be even more significant than other factors like race in 
drawing lines between who does seek out and receive fertility treatment and who does not. 
Nonetheless, all data should be considered and analyzed with the understanding that many of 
these factors interact in such a multiplicative, complex way (Crenshaw, 1989). It is important to 
recall that these results are even more surprising and disturbing when considered in conjunction 
with the fact that African American and Hispanic women have reported infertility not at equal 
levels with white women, but at higher rates (Abma et al, 1997). The very populations that are 
reporting infertility at the highest rates are receiving the least amount of treatment.  
Another paper published one year after Jain & Hornstein’s 2005 article emphasizes this 
finding. Bitler & Schmidt (2006) compiled data from over 30,000 women documented in the 
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CDC National Survey for Family Growth (NSFG) using data from 1982-2002 who were of 
childbearing potential (aged 15-44 years). The outcomes of infertility status, impaired fecundity, 
and ever-use of infertility treatment by women in states with mandated fertility treatment 
insurance coverage were compared to those of women in states without insurance mandates. 
The main results of the Bitler & Schmidt study were as follows. While insurance mandates do 
increase the overall infertility service utilization rates in states with mandates, the rate of 
utilization mainly only increased in communities of older white women who were in possession 
of advanced degrees—a community of high socioeconomic status that is traditionally 
overrepresented in fertility clinics (Bitler & Schmidt, 2006; Chandra et al, 2014). This study also 
had more specific findings that revealed the existence of persistent disparities and 
infertility/impaired fecundity rates even in states with mandated insurance.  
According to the NSFG surveys, infertility in Massachusetts was more common for black 
and Hispanic women than for white women. Both infertility and impaired fecundity were more 
common for those who did not graduate high school or who possessed a high school diploma as 
their highest education level compared to women with 4-year college degrees. Lastly, women 
who were older, white, and received a college education or higher were more likely to have ever 
received treatment for trouble conceiving (Bitler & Schmidt, 2006). This further exemplifies how 
disparities in fertility treatment access across both racial lines and socioeconomic lines are often 
not eradicated by the implementation of state-mandated fertility service coverage. Finally, 
another paper analyzed these disparities in access to and utilization of fertility treatment across 
racial lines from the perspective of time. Once again looking at individuals in states with 
mandated insurance coverage, this paper found that African American women experienced a 
significantly longer average duration of infertility before seeking treatment of 4.3 years 
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compared to shorter 3.3 years experienced by white women (p-value: 0.03) (Jain, 2006). Again, 
it is important to note that the population of interest in the aforementioned studies are insured 
people residing in states with mandated fertility insurance coverage. This potentially excludes 
the people residing in the 33 states without insurance coverage mandates and the 11.7% of 
reproductive aged women (aged 15-44 years) nationwide who were uninsured as of 2017 
regardless of state of residence (Guttmacher Institute, 2018). Because insurance mandates only 
help those who live in applicable states and have insurance, increasing fertility coverage 
mandates without also addressing more deeply rooted health care inequalities and access to 
insurance could possibly further exacerbate inequalities on the grounds of race and 
socioeconomic status.  
 
Explaining the Disparities: Implicit and Explicit Exclusion from Reproduction 
 
In recent decades, social scientists particularly from the realm of sociology have 
highlighted the experiences and realities of women who are excluded from fertility treatments 
based on their status as low-SES, non-white, or another medically marginalized identity. These 
exclusions come down to two categories: explicit exclusion from fertility treatment and implicit 
exclusion from fertility treatment. While the discrimination and exclusion faced across racial 
lines was slightly different, low-income women of any race similarly experience exclusion from 
the realm of fertility treatment both explicitly and implicitly based on the biased notion that poor 
people are overly fertile and therefore must be controlled by medical professionals. 
 
Explicit Exclusion 
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Black women are often discouraged from reproducing by doctors and other medical 
providers in ways that are directly and explicitly exclusionary. One participant from Ann Bell’s 
in-depth interviews with low-SES women was a black woman who many years before had 
sought medical treatment for a miscarriage. While pursuing medical attention for a miscarriage, 
the woman cited being “scared” into not having any more kids and was made to feel as though 
“they just didn’t want me to have any kids at all. At all. And that was sad.” (Bell, 2010). 
Especially when considered together with past atrocities committed by medical providers in the 
United States like the surgical sterilization of ethnic minorities including black women in the 
1970s, it becomes increasingly clear why negative physician-provider interactions like the one 
described have such a directly negative, exclusionary effect (Shreffler et al, 2016). Women in 
situations like this are taught to trust and be obedient to medical providers based on the 
clinicians’ perceived power and legitimacy granted to them through their association with the 
powerful cultural institution that is biomedicine (Steinberg, 1997). Thus, when women are being 
directly discouraged from reproduction based on the views of medical providers or the society 
that they reflect, doctors and other staff can mask their bias within the guise of concern and 
medical necessity. After women experience numerous medical encounters in which providers 
discourage them from getting pregnant, many women find themselves internalizing the notion 
that they should not reproduce. This example shows how the fieldwork of social scientists like 
Ann Bell can help us more deeply and therefore more completely understand statistics like that 
of Tarun Jain’s finding that black women endured a significantly longer period of untreated 
infertility than their white counterparts (Jain, 2006). By analyzing these demographic statistics 
through the work of social scientists, we gain a better chance of creating actual solutions to the 
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disparities in fertility treatment access that continue to plague the US despite many calls for 
change. 
Another black woman interviewed by Bell who had experienced fertility struggles for 
many years explained that she had not yet seen a doctor to address her difficulties becoming 
pregnant. She was hesitant to see her doctor because she did not believe they had any valuable 
information for her and expressed that in her experience, all doctors have done is try to “talk you 
out of getting pregnant” (Bell, 2010). Likely a combination of distrust for the medical 
establishment after years of mistreatment and internalization of the notion that she was unfit to 
be a mother, this woman simply accepted her inability to become pregnant as her unalterable fate 
and did not take action to ameliorate her fertility struggles. This is a vivid example of how 
society’s ideas about what kind of women are unfit to be mothers are exercised through direct 
doctor-patient interactions, both reflecting our society’s notions about motherhood while also 
continuing to actively shape the landscape of motherhood in a way that encourages the 
reproduction of only certain women in society. 
 In addition to being a black woman, the woman in the previous example was neither 
married nor in a monogamous relationship. Recalling the study that found that one in five 
medical providers refused inclusion in ART programs to unmarried women, some single women 
thereby experience direction exclusion from assistance becoming pregnant (Gurmankin, Caplan 
& Braverman, 2005). This finding takes on another level of significance when considered in 
conjunction with the demographical information that black women are more likely to be single 
than white woman (Raley, Sweeney, & Wondra, 2016). Because these data suggest black women 
are more likely to be single than white women and that single women are more often denied 
fertility assistance than are married women, black women are faced with an even higher 
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likelihood of being directly excluded from fertility services because of discrimination on grounds 
of both racial and marital status.  
All of this information considered together illustrates how women who are black, low-
income, unmarried, or any combination of these intersecting identities are effectively 
discouraged from reproduction. Especially women who are black, low-income, and single are 
viewed as burdens to both the medical system and to society whose reproduction should be 
controlled and limited, not encouraged. Such notions are fueled by contrasting stereotypical 
representations of the infertile, middle to upper-class, married, heterosexual white woman who 
quietly yearns to fulfill her womanly role of a stay-at-home mom and the poor or working class, 
unmarried, excessively fertile black “welfare queen” who is indifferent about her role as a 
mother (Sandelowski & De Lacey, 2002). First, this stereotype has been proven false by findings 
like the one previously discussed that reveals that black women actually experience infertility 
more than white women (Wellons et al, 2009). This stereotype must persist then, because it can 
be used by biased individuals and society at large to justify and naturalize women of color’s 
exclusion from “infertility narratives” and subsequent fertility treatment services (Sandelowski & 
De Lacey, 2002). In this way, medical providers can guard the entrance to the realm of 
motherhood by directly excluding those that are not deemed by society to be fit mothers and 
include those that are deemed fit mothers. Until society addresses the deeply ingrained biases 
that continue to inform these often classist and racist notions of motherhood, it is unlikely that 
these stereotypes and their negative effects will fully be eliminated. 
Low-income white women do not generally experience medical discrimination to the 
same extent as or in exactly the same manner that low-income black women do. Poor white 
women are mainly only discriminated against per their low socioeconomic status and not the 
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“double discrimination” on both socioeconomic and racial grounds (Crenshaw, 1989). Even so, 
low-income white women are also explicitly excluded from the realm of fertility treatments. 
Another low-income woman in Bell’s sociological analysis was a young, poor white woman who 
explained that in prior years in exchange for receiving any medical services from a low-income 
health clinic, she had to agree to go onto a semi-permanent form of birth control called Depo-
Provera. Despite the young woman’s status as sexually inactive and without any plans to become 
sexually active, the clinic’s social workers forced the woman to take Depo-Provera for six years 
stating that they were simply enforcing the clinic’s “fertility policy” (Bell, 2010). This woman 
blames the fertility issues she faced at the time of her interview on her prolonged usage of the 
Depo-Provera. Whether or not this is actually true, encounters like this show how individuals 
grow to mistrust the medical system especially in matters of fertility. In this particular example, 
the health clinic’s fertility policy explicitly excludes this woman from becoming a mother in the 
near future should she choose to do so. But perhaps more troubling is the policy’s implicit 
implementation of eugenic logic that low-income women are excessively fertile and unfit 
mothers, therefore their reproduction must be contained and controlled by the middle and upper 
classes through the institution of medicine (Steinberg, 1997). These explicit exclusions from 
reproduction make affected women feel uncomfortable seeking biomedical treatment and often 
cause them to internalize the notion that they are not fit to be a mother. 
Implicit Exclusion 
Women who are not deemed to be fit mothers according to society’s hegemonic norms of 
motherhood can experience implicit exclusion from fertility assistance services after many years 
of directly exclusionary medical interactions, but the implicit exclusion can also be entirely 
unique. To give an example of the former, one paper argued that some individuals from 
  Gilbert 33 
 
medically marginalized populations like women of color have grown to distrust the medical 
establishment as a whole after repeated exposure to discrimination during medical appointments 
(White & McQuillan, 2006). After this “medical anxiety” has developed, certain women 
interviewed reported that they did not trust the medical establishment enough to even seek 
biomedical treatment when they began to experience infertility (White & McQuillan, 2006). This 
source serves as another possible explanation for the 2006 finding that black women endured 
longer durations of infertility before seeking assistance (Jain, 2006). If findings like those of 
Jain, Wellon et al, and others continue to be discussed only by other demographers and not 
contextualized through the work of social scientists, dialogue surrounding low fertility service 
access and usage rates among groups like black women will lack the nuanced complexity that is 
required to make strides toward actually addressing and eliminating these inequalities. 
Other social science sources also help to unpack the idea of implicit exclusion from 
fertility service. For example, a paper by White & Greil (2006) attempts to explain why women 
of higher SES report higher utilization rates by citing specific sociocultural barriers experienced 
by people who are non-white and of lower SES. Some of these barriers include language barriers 
between patients and their providers, communication style differences rooted both in cultural 
differences and power dynamics, notions of privacy, and biases held by providers (White & 
Greil, 2006). Bell elaborates on this idea, providing specific instances that though not directly 
exclusionary, did ultimately prevent low-SES women from following through with the fertility 
services they sought. For example, the appointment-based nature of medical appointments that 
take place within the 9 AM-5 PM workday cater to higher SES salaried workers or women who 
do not work. But to low-income women, however, missing hourly work for these appointments 
sometimes proved too financially burdensome to continue (Bell, 2010). In this way, low-SES 
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women experiencing struggles conceiving are effectively forced to choose between having a 
child and keeping a job in order to earn a living.  
Inclusion of social science sources in dialogue about fertility service disparities provide a 
level of detail, nuance, and truth about the everyday realities of certain populations of women 
that must be used in future discussions to help generate tangible and effective solutions to 
eliminating these disparities. Additionally, overarching disparities in the healthcare system must 
be addressed alongside more fertility-specific disparities to achieve the best possible result. 
Lastly, this paper has illustrated how interdisciplinary approaches allow for a novel and 
advantageous way of tackling matters of healthcare inequities and can hopefully be used as a 
model for future research endeavors. 
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